Therapeutic Clinical Intelligence: Rheumatoid Arthritis

Table of Contents

Section 1 - Executive Summary6

Section 2 - Market Leaders & Near-Term Competitors 13

• Enbrel (etanercept)16
• Remicade (infliximab)26
• Humira (adalimumab) 36
• Rituxan (rituximab) 46
• Orencia (abatacept) 56
• Actemra (tocilizumab) 69
• Cimzia (certolizumab pegol) 96
• Simponi (Golimumab) 104
• Ocrelizumab115
• Arzerra (ofatumumab) 122
• CP-690,550128

Section 3: Mid-Stage Competition to Watch 142

• TRU-015143
• INCB018424 157
• R788 (fostamatinib)164
• Belimumab (LymphoStat-B)172
• AZD9056 175
• canakinumab (ACZ885) 180

Section 4 a: Phase 2 Pipeline: Biologics 183

• LY-2127399 184
• CNTO-136 187
• ALD-518 189
• ART-621 191
• MDX-1100194
• BT-061197
• T-1h-mAb (h-T1)199
• 315234 200
• KB-002/KB-003 203
• LY-2189102205
• AIN-457207
• Atacicept 209
• MM-093 214

Section 4 b: Phase 2 Pipeline: Small-Molecule (Orals) 219

• 681323220
• 856553225
• BMS-582949 227
• PH-797804 230
• KC-706 233
• RWJ-445380 234
• AZD5672 236
• CH-1504 238
• 4SC-101 243
• Panaclar 245
• DE-096 247
• ARRY-162 248
• Apilimod257
• TAK-783259
• CF-101 261
• SSR-150106 265
• CE-224535 267
• Rabeximod 270
• PG-760564 272
• Rimacalib274
• PMI-001276
• K-832278
• VX-702 279
• LX-2931 282
• HE-3286 287

Section 5: On the Radar: Overview of Phase 1 RA Programs 289

• Small Molecules 290
• Biologics293
• Undisclosed Programs297

Section 6: Discontinued RA Programs298

Section 7 - Appendix300

• Disclaimer 301